Bortezomib in patients with renal impairment

Renal function in newly diagnosed multiple myeloma - A demographic study of 1353 patients

(2010) Lene Meldgaard Knudsen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Role of NF-κB in the Regulation of Cytochrome P450 Enzymes

(2009) Beshay Zordoky et al.   CURRENT DRUG METABOLISM

Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA

(2009) Fortunato Morabito et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study

(2009) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

Staging of Chronic Kidney Disease: Time for a Course Correction

(2008) C. Bauer et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

(2008) J F San-Miguel et al.   LEUKEMIA

Pathogenesis and treatment of renal failure in multiple myeloma

(2008) M A Dimopoulos et al.   LEUKEMIA

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

(2008) Maria Roussou et al.   LEUKEMIA & LYMPHOMA

IKK/NF-κB signaling in intestinal epithelial cells controls immune homeostasis in the gut

(2008) M Pasparakis   Mucosal Immunology

Plasma Cell Disorders: An Historical Perspective

(2008) N. C. Munshi   Hematology-American Society of Hematology Education Program